×

3-[4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl]octane—or heptane-nitrile as JAK inhibitors

  • US 9,216,984 B2
  • Filed: 11/08/2013
  • Issued: 12/22/2015
  • Est. Priority Date: 05/22/2009
  • Status: Active Grant
First Claim
Patent Images

1. A method of treating a disease or disorder selected from cachexia, rheumatoid arthritis, psoriasis, polycythemia vera (PV), essential thrombocythemia (ET), myeloid metaplasia with myelofibrosis (MMM), chronic myelogenous leukemia (CML), chronic myelomonocytic leukemia (CMML), multiple myeloma, pancreatic cancer, leukemia, lymphoma, breast cancer, acute myelogenous leukemia, acute lymphoblastic leukemia, and Castleman'"'"'s disease in a patient comprising administering to said patient a therapeutically effective amount of a compound selected from 3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]octanenitrile;

  • and 3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]heptanenitrile;

    or a pharmaceutically acceptable salt thereof.

View all claims
  • 3 Assignments
Timeline View
Assignment View
    ×
    ×